Geode Capital Management
GEVA

Geode Capital Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Geode Capital Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-158,319
Closed -$15.4M – 4021
2015
Q1 		$15.4M Buy
158,319
+30,667
+24% +$3.25M 0.01% 1079
2014
Q4 		$11.8M Buy
127,652
+5,011
+4% +$395K 0.01% 1187
2014
Q3 		$8.44M Sell
122,641
-17
-0% -$1.22K 0.01% 1396
2014
Q2 		$12.9M Buy
122,658
+9,331
+8% +$794K 0.01% 1111
2014
Q1 		$9.4M Buy
113,327
+14,348
+14% +$1.33M 0.01% 1295
2013
Q4 		$6.41M Buy
98,979
+10,907
+12% +$647K ﹤0.01% 1509
2013
Q3 		$5.58M Buy
88,072
+36,605
+71% +$1.8M ﹤0.01% 1483
2013
Q2 		$2.16M Buy
+51,467
New +$2.35M ﹤0.01% 1985

Geode Capital Management's GEVA Position: Q2 2015 in Review

Geode Capital Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 158,319 shares — an estimated $15.4M sold.

Geode Capital Management first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $15.4M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Geode Capital Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Geode Capital Management sold 158,319 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $15.4M.
  • Geode Capital Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Geode Capital Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $15.4M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Geode Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.